subscribeSubscribe
price-trendAsk Us
Teva recall: Tainted blood pressure drugs continue to show up in U.S. supply

Teva recall: Tainted blood pressure drugs continue to show up in U.S. supply
Eric Palmer FIERCE PHARMA
14 Jun 2019
Share Share
Vivimed Life Sciences Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP

Vivimed Life Sciences Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP
FDA
04 May 2019
Share Share
Over 100 lots of losartan tablets recalled after NMBA detected

Over 100 lots of losartan tablets recalled after NMBA detected
Maggie Lynch IN-PHARMATECHNOLOGIST
30 Apr 2019
Share Share
EMA Urges Pioglitazone Manufacturers to Check for Nitrosamine Impurities

EMA Urges Pioglitazone Manufacturers to Check for Nitrosamine Impurities
Zachary Brennan RAPS
26 Apr 2019
Share Share
Legacy Pharmaceutical Packaging, Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg

Legacy Pharmaceutical Packaging, Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 50mg
FDA
25 Apr 2019
Share Share
To Prevent Losartan Shortages, FDA Allows Higher Impurity Levels

To Prevent Losartan Shortages, FDA Allows Higher Impurity Levels
Zachary Brennan RAPS
22 Mar 2019
Share Share
FDA updates on recalls of valsartan, losartan and irbesartan

FDA updates on recalls of valsartan, losartan and irbesartan
FDA
20 Mar 2019
Share Share
Legacy Pharmaceutical Packaging Issues Recall of Losartan Potassium Tablets

Legacy Pharmaceutical Packaging Issues Recall of Losartan Potassium Tablets
FDA
19 Mar 2019
Share Share
Camber Pharmaceuticals Voluntarily Recalls Losartan Potassium Tablets

Camber Pharmaceuticals Voluntarily Recalls Losartan Potassium Tablets
FDA
01 Mar 2019
Share Share
Update on the EDQM review of CEP applications for sartan substances (4 Feb 2019)

Update on the EDQM review of CEP applications for sartan substances (4 Feb 2019)
EDQM
04 Feb 2019
Share Share